Back to catalogue
№ 169 45 filings · 2021-07-19 → 2026-07-17

EAGLE EYE SOLUTIONS GROUP PLC

EYE
Technology Share price 497p Market cap £150m Overall fit 665 /1000

Genuine AI-receiver via EagleAI with high SaaS operating leverage, fortress balance sheet, and valuation that doesn't require the bull case — scores strongly across all three pillars, though customer concentration and execution risk on medium-term targets prevent a top-band score.

Fair value range 550p–750p Mid case · £196m
Absolute upside +31% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Clean, well-disclosed SaaS KPIs (ARR +31%, NRR 111%, churn 0.4%)
  • Net cash £16m and consistent free cash generation
  • Two consecutive beats vs. rebased consensus in FY26
Limits the call
  • £100m/30% EBITDA medium-term target requires both revenue doubling and 900bps margin expansion
  • Tier-1 customer concentration proven fragile by NRS loss
Methodology

Forward EV/EBITDA on FY27 estimates cross-checked with EV/ARR

In one line · bull case

AI-embedded vertical SaaS with net cash, 31% ARR growth and a credible OEM channel unlock, available at ~3x EV/ARR and ~13x FY27 EBITDA — pays you to wait for the £100m revenue vision.

In one line · biggest risk

Loss of another Tier-1 customer (as NRS demonstrated) could reset the growth and margin trajectory materially given concentrated enterprise revenue mix.

Drivers
AI beneficiary 65 /100
EagleAI revenue +34% to £7.7m in FY26, embedded AI decisioning captured by Eagle Eye at per-transaction economics, not press-release AI.
Operating leverage 75 /100
74% SaaS direct margin, 87% recurring mix, high fixed staff/infra cost base — 30% EBITDA target implies material incremental margin.
Earnings vs expectations 70 /100
Material beat in FY26 (EBITDA £9.8m vs. £7.0m consensus) and H1 FY26 both delivered ahead of Board expectations.
Growth momentum 70 /100
ARR +31% ex-NRS, EagleAI +34%, 8 new multi-year wins in H1 FY26, OEM channel starting to contribute.
Moat 55 /100
Deep POS integrations, long contracts (5-year Woolworths renewal, John Lewis) and scale create switching costs but market has credible competitors.
Earnings quality 65 /100
Meaningful capitalised development (£2.7m H1) and IFRS 15 deferrals require attention but cash conversion is real; adjusted metrics are consistent.
Management quality 60 /100
Tim Mason (ex-Tesco Deputy CEO) executed cleanly through NRS loss with cost reset and OEM signing; disclosure is candid.
Cyclicality 25 /100
Subscription SaaS with predictable transaction volumes, some indirect retail-spend exposure but low direct cyclicality.
Leverage 15 /100
£16m net cash, no drawn debt, £10m undrawn RCF — fortress balance sheet.

Eagle Eye Solutions Group PLC (EYE) — Investment Research Note

Executive summary

Eagle Eye is an AI-native SaaS platform (AIR + EagleAI) that powers loyalty and personalised promotions for enterprise retailers globally — Tesco, Morrisons, Asda, Loblaws, Carrefour, Woolworths and, increasingly, non-grocery brands like Subway and easyJet. Across the covered period the group scaled revenue from ~£20m to £48m while turning EBITDA-positive, then absorbed the loss of the Neptune Retail Solutions (NRS) contract in June 2025 — resetting FY26 revenue to £46.7m but re-accelerating underlying ARR to £44.5m (+31%) with a first OEM channel live via a large global enterprise software vendor. The single most important valuation point today is whether the medium-term £100m revenue / +30% EBITDA margin target is credible: at £142m market cap the share price does not yet require the bull case, but does discount some execution.

Fair value estimate

  • Range: 550p – 750p per share (implied market cap £166m – £226m).
  • Mid: ~650p / £196m — implies ~40% upside vs. 465p / £142.1m today.
  • Methodology: forward EV/EBITDA on FY27 estimates, cross-checked against EV/ARR and a scenario DCF.
  • Key assumptions:
    • FY27 revenue £53–56m (double-digit growth restored per 2026-07 trading update; ARR £44.5m exit + NRR 111% + OEM ramp).
    • FY27 adjusted EBITDA £12–14m (25% margin en route to the stated 20% exit-run-rate in H2 26 and 30% medium term) 2026-07-17 trading update.
    • Multiple of 15–18x forward EBITDA — defensible for a >20% ARR-growth, high-gross-margin vertical SaaS with net cash.
    • +£16m net cash added to EV 2026-07-17 trading update.
  • Downside sanity check: even holding EBITDA at ~£10m and applying 12x gives ~£120m EV + £16m cash = ~£136m, i.e. broadly the current market cap — limited downside if the growth pivot stalls but hits margin target.

Sector context

  • Confirmed: Technology / Software & SaaS (vertical: retail loyalty & promotions).
  • Quality/growth/leverage profile is above typical UK small-cap tech peers: 87% recurring revenue, 111% NRR ex-NRS, low churn (0.4%), net cash balance sheet, and a genuinely AI-integrated product line growing 34% 2026-07-17 trading update; 2026-03 half-year.
  • Listed peers/comparables: dotDigital (DOTD), Kin & Carta / Ideagen (private), and larger AI-inflected loyalty tech names such as Marigold, Cheetah Digital (private) or Israel-listed Similarweb; internationally comparable to segments of Braze and Cordial on the personalisation side.

Investment thesis

  1. Genuine AI-receiver via EagleAI + AIR embedded in enterprise retail workflows — EagleAI revenue +34% to £7.7m in FY26, now processing "2.8bn customer interactions per minute" and generating "an average of one billion AI-generated promotions per month." The AI value accrues to Eagle Eye (per-seat/per-transaction expansion), not to hyperscalers 2026-03-17 half-year; 2026-07-17 trading update.
  2. OEM channel is a genuine scale lever — two blue-chip European clients already secured via the global OEM partner with c.£2m initial ARR, materially revenue-generating from FY27; management frames the OEM as capable of "doubling the size of the business in the medium term" given the vendor's 300,000+ customer base 2025-09-16 final results; 2026-07-17 trading update.
  3. Operating leverage snapping back post-NRS reset with valuation not yet reflecting it — H2 FY26 EBITDA margin exit-rate materially exceeded the 20% target on a substantially higher SaaS mix (87% of revenue), and net cash grew 31% to £16.1m despite share buybacks. Current EV/ARR ~2.8x is modest for 31% ARR growth 2026-07-17 trading update.

Key risks

  1. Customer concentration and single-contract fragility — the NRS loss (June 2025) removed a major high-margin revenue line and depressed FY26 headline; a similar loss at Tesco, Asda, Morrisons, or Loblaws would be very material given 87% recurring mix concentrated in Tier-1 retailers 2025-09-16 final results.
  2. AI competitive risk from hyperscalers and CDPs — retailers can rebuild personalisation on Google Cloud/Braze/Salesforce with generative AI. Eagle Eye's moat depends on execution and integration depth, not on unique data or IP; not disclosed but inferred.
  3. Medium-term targets require both revenue and margin expansion simultaneously — reaching £100m revenue and 30% EBITDA (from £46.7m/21%) implies both a doubling of revenue and 900bps of margin expansion. Any slippage in the OEM ramp, US pipeline or NRR compression would push out the timeline materially 2026-05-21 Capital Markets Day.

Operating leverage

Fixed-cost share is high: net staff costs (~54% of adjusted opex) and IT infrastructure (~27%) do not scale linearly with revenue. Direct/SaaS gross margin already sits at 70–74% (SaaS margin 74% in H1 FY26) and the business is guiding to a 20% exit EBITDA margin run-rate in FY26 vs. FY24's 24% headline. Management's own model says every 10p of incremental revenue reinvests ~30p in growth and drops ~50p to margin, suggesting a >50% incremental EBITDA margin at current scale 2025-03-17 half-year; 2026-03-17 half-year. Applying that to a 15–20% revenue beat on £47m base implies an additional ~£4–5m of EBITDA on top of the guided ~£11–13m FY27 base — i.e. a plausible doubling of profit on a modest revenue surprise. The stated medium-term target of 30% EBITDA on £100m revenue (£30m EBITDA vs. £9.8m today) is the visible inflection point.

Value-trap signals

None identified. The NRS loss is a discrete, disclosed event; underlying KPIs (ARR +31%, NRR 111%, net cash +31%, ex-NRS revenue +21%) are all trending positively. No dividend cuts, no going-concern language, no related-party issues, no debt.

Earnings vs. expectations

  • FY25 (Sep 2025): Revenue £48.2m in line with pre-NRS revised guidance; adjusted EBITDA £12.2m up 8% — met/small beat.
  • H1 FY26 (Jan 2026 trading update): Company guided FY26 profits "comfortably ahead" of consensus (which was £5.9m EBITDA); H1 EBITDA £4.3m, 18% margin vs. Board expectations of lower — beat.
  • FY26 (Jul 2026 trading update): Consensus at the time was Revenue £45.4m / EBITDA £7.0m; delivered £46.7m and £9.8m — material beat.
  • Pattern: Post-NRS reset, the group has delivered two consecutive beats vs. management/consensus. Prior pattern (FY24, FY25) was in-line to modest beat. Trend is positive.

Conviction: 3 — moderate

Anchors: (1) High-quality, well-disclosed SaaS metrics (ARR, NRR, churn) that support the growth trajectory; (2) Genuine cash generation and net cash position — reduces downside risk; (3) Recent record of beating rebased expectations. Limits: (1) The £100m/30% EBITDA target is a 3–5 year vision with material execution risk on OEM and US pipeline conversion; (2) EBITDA can move sharply with one enterprise customer loss (NRS proved this).

Driver scoring rationale

Eagle Eye scores well for this investor: genuine AI-receiver via EagleAI (not just marketing language), high operating leverage inherent to the SaaS model, valuation that doesn't require heroic assumptions, and downside protection from net cash and 87% recurring revenue. The main reservation is scale — at £142m market cap with concentrated Tier-1 customer exposure and reliance on OEM ramp, it's not the "own with high conviction" band, but comfortably a strong buy.

Filings consulted · 43

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-17Fy26 Trading Update And Notice OF Results2026-07-17_9673549_fy26-trading-update-and-notice-of-results.md0.85
  2. 2026-05-21Capital Markets Day2026-05-21_9578964_capital-markets-day.md0.95
  3. 2026-04-27Notice OF Capital Markets Day2026-04-27_9538189_notice-of-capital-markets-day.md0.95
  4. 2026-03-17Half Year Results2026-03-17_9476969_half-year-results.md0.90
  5. 2026-01-20H1 Fy26 Trading Update And Notice OF Results2026-01-20_9367659_h1-fy26-trading-update-and-notice-of-results.md0.85
  6. 2025-11-19Result OF Agm2025-11-19_9244711_result-of-agm.md0.26
  7. 2025-11-19Agm Trading Statement2025-11-19_9242602_agm-trading-statement.md0.72
  8. 2025-10-232025 Annual Report And Accounts And Notice OF Agm2025-10-23_9190824_2025-annual-report-and-accounts-and-notice-of-agm.md0.81
  9. 2025-09-16Final Results2025-09-16_9109712_final-results.md0.85
  10. 2025-07-15Fy25 Trading Update2025-07-15_8978967_fy25-trading-update.md0.55
  11. 2025-06-30Acquisition OF Promotional Payments Solutions2025-06-30_8953265_acquisition-of-promotional-payments-solutions.md0.49
  12. 2025-03-17Half Year Results2025-03-17_8781237_half-year-results.md0.58
  13. 2025-01-13H1 Fy25 Trading Update Amp Notice OF Results2025-01-13_8684215_h1-fy25-trading-update-amp-notice-of-results.md0.55
  14. 2024-11-21Result OF Agm2024-11-21_8565041_result-of-agm.md0.20
  15. 2024-11-21Agm Trading Statement2024-11-21_8563171_agm-trading-statement.md0.55
  16. 2024-10-222024 Annual Report And Accounts And Notice OF Agm2024-10-22_8502078_2024-annual-report-and-accounts-and-notice-of-agm.md0.62
  17. 2024-09-18Final Results2024-09-18_8422196_final-results.md0.65
  18. 2024-07-23Trading Update2024-07-23_8324530_trading-update.md0.55
  19. 2024-03-19Half Year Results2024-03-19_8094035_half-year-results.md0.41
  20. 2024-01-16H1 Trading Update And Notice OF Results2024-01-16_7990492_h1-trading-update-and-notice-of-results.md0.38
  21. 2023-11-16Result OF Agm2023-11-16_7886534_result-of-agm.md0.14
  22. 2023-11-16Agm Trading Statement2023-11-16_7884380_agm-trading-statement.md0.38
  23. 2023-10-192023 Annual Report And Accounts And Notice OF Agm2023-10-19_7827738_2023-annual-report-and-accounts-and-notice-of-agm.md0.43
  24. 2023-09-26Replacement Final Results2023-09-26_7779131_replacement-final-results.md0.45
  25. 2023-09-19Final Results2023-09-19_7763244_final-results.md0.45
  26. 2023-07-11Trading Update2023-07-11_7624347_trading-update.md0.21
  27. 2023-03-14Half Year Results2023-03-14_7432834_half-year-results.md0.23
  28. 2023-01-18H1 Trading Update And Notice OF Results2023-01-18_7442758_h1-trading-update-and-notice-of-results.md0.21
  29. 2023-01-03Completion OF Acquisition And Issue OF Equity2023-01-03_7307934_completion-of-acquisition-and-issue-of-equity.md0.19
  30. 2022-11-17Result OF Agm2022-11-17_7414077_result-of-agm.md0.07
  31. 2022-11-16Results OF 7M Placing2022-11-16_7375622_results-of-7m-placing.md0.17
  32. 2022-11-16Proposed Acquisition And Launch OF Placing2022-11-16_7374794_proposed-acquisition-and-launch-of-placing.md0.19
  33. 2022-10-272022 Annual Report And Accounts And Notice OF Agm2022-10-27_7160839_2022-annual-report-and-accounts-and-notice-of-agm.md0.24
  34. 2022-09-21Final Results2022-09-21_7415094_final-results.md0.25
  35. 2022-07-19Trading Update2022-07-19_7036827_trading-update.md0.21
  36. 2022-05-20Trading Update2022-05-20_6935178_trading-update.md0.21
  37. 2022-03-16Half Year Results2022-03-16_6966257_half-year-results.md0.23
  38. 2022-01-27H1 Trading Update And U S Customer Win2022-01-27_6996528_h1-trading-update-and-u-s-customer-win.md0.21
  39. 2021-11-18Result OF Agm2021-11-18_6792130_result-of-agm.md0.07
  40. 2021-11-18Agm Statement2021-11-18_6790619_agm-statement.md0.10
  41. 2021-10-252021 Annual Report And Accounts And Notice OF Agm2021-10-25_6569134_2021-annual-report-and-accounts-and-notice-of-agm.md0.24
  42. 2021-09-22Final Results2021-09-22_6514098_final-results.md0.25
  43. 2021-07-19Trading Update2021-07-19_6656034_trading-update.md0.09

This research note was authored by a large language model after reading 45 regulatory filings published between 2021-07-19 and 2026-07-17. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.